Targeting the STING–cGAS signaling pathway in laryngeal cancer might potentially improve current therapeutic approaches, and elevated STING expression could be considered as a predictive biomarker in future clinical trials, including STING agonists. This evidence concerns the gene STING1 and laryngeal carcinoma.